Trial Profile
The Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 09 Mar 2017 Planned primary completion date changed from 31 Dec 2018 to 8 Mar 2017.
- 09 Mar 2017 Planned End Date changed from 31 Dec 2018 to 8 Mar 2017.
- 09 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.